By Dow Jones Business News,
January 23, 2014, 08:44:00 AM EDT
By Everdeen Mason
Pfizer Inc. ( PFE ) said its treatment for chronic lower back pain met the primary efficacy endpoint in a Phase 3 study.
The drug maker's investigational agent ALO-02 is an oxycodone hydrochloride and naltrexone hydrochloride extended-
release capsule meant to treat people with moderate-to-severe chronic low back pain.
During the 12-week study to test the drug's efficacy and safety, patients were given 10 to 80 milligrams of ALO-02
twice a day during a four- to six-week period. Some then continued on the same dose regimen, while others were tapered
to a placebo.
Pfizer said the study revealed that ALO-02 treated pain better than a placebo, but caused side effects such as nausea,
vomiting and diarrhea in some patients.
The study's results will be submitted for presentation at medical congresses and publication in a peer-reviewed
journal, the company said.
Pfizer has posted repeated revenue drops in recent quarters as it continues to feel sales pressure from generic
competition on its top-selling drugs. The company slowed its research-and-development cuts last quarter as it enters
late-stage clinical trials on several experimental drugs.
Pfizer said earlier this week that its clinical study of a treatment to help smokers quit met primary and secondary
endpoints. The company studied the effects of its Chantix and Champix smoking-cessation products on patients who were
unable or unwilling to quit smoking within a month.
Pfizer shares fell a penny to $31.26 in premarket trading. As of Wednesday's close, the stock is up 17% in the past 12
Write to Everdeen Mason at email@example.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
Copyright (c) 2014 Dow Jones & Company, Inc.